Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PAXMEDICA, INC.

(PXMD)
SummaryNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder in the Research Pipeline Program

08/19/2021 | 08:00am EST

PaxMedica, Inc. announced that it has been selected to present the results from its Phase 2 dose-ranging clinical trial evaluating PAX-101 (IV suramin), an investigational drug with a proposed novel mechanism of action that the Company is developing as a potential treatment for the core and related symptoms of Autism Spectrum Disorder (ASD). This trial, using low doses of suramin once monthly, expanded on earlier published reports of the potential for intravenous suramin as a treatment for the core and related symptoms of ASD and lends support to purine mediated mechanisms playing an important role in the treatment of ASD. The Phase 2 study was a dose-ranging, randomized, double-blind, placebo-controlled, multidose trial evaluating the safety and efficacy of PAX-101 in patients diagnosed with moderate to severe autism spectrum disorder. In the 14-week trial, patients were randomized 1:1:1 to receive 10mg/kg of PAX-101, 20mg/kg of PAX-101 or placebo infusions every 4 weeks. Infusions were administered at baseline, week 4 and week 8 with the end of study visit at week 14. The primary endpoint of the study was the change between baseline and Week 14 in the Aberrant Behavior Checklist (ABC) composite score of core symptoms (ABC Core) including ABC-II (lethargy/social withdrawal), ABC-III (stereotypy) and ABC-V (inappropriate speech). Secondary outcome measures included: ABC individual sub-scores, Clinical Global Impression of Improvement scale, adapted for autism (CGI-I), Autism Diagnostic Observation Scale, version 2 (ADOS-2) changes, Autism Treatment Evaluation Checklist (ATEC), and safety and tolerability.


ę S&P Capital IQ 2021
All news about PAXMEDICA, INC.
10/28Paxmedica, Inc. Presents Clinical Data and New Analyses from A Phase 2 Trial of Pax-101..
CI
08/19PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
02/09PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2020PaxMedica, Inc. announced that it has received $3 million in funding
CI
2020PaxMedica, Inc. announced that it expects to receive $3 million in funding
CI
2020PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million.
CI
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -0,60 M - -
Net cash 2019 0,02 M - -
P/E ratio 2019 -
Yield 2019 -
Capitalization 59,1 M 59,1 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 3
Free-Float 26,3%
Income Statement Evolution
Managers and Directors
Joseph Lucchese Chief Financial Officer
Zachary Rome Chief Operating Officer & Director
Karen A. Dawes Independent Director
Paul Kevin Wotton Independent Director
Robert F. Apple Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PAXMEDICA, INC.0.00%59
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-40.81%24 321